Resource Center
All of your clinical trial imaging workflow resources in one place.
Fixing Site Reads Without Burning Out the Readers
Site reads are broken. This article shows how to fix them without burning out your readers.
Listen to Podcast
Listen to Podcast
In this Labiotech.eu article on AI in oncology, Yunu CEO Jeffrey Sorenson shares insights on how AI streamlines clinical trials, enhances patient outcomes, and accelerates innovative therapy discovery. He emphasizes that integrating AI into cancer research could lead to more personalized and effective treatments, drastically improving patient outcomes and reducing costs.
In this Labiotech.eu article on AI in oncology, Yunu CEO Jeffrey Sorenson shares insights on how AI streamlines clinical trials, enhances patient outcomes, and accelerates innovative therapy discovery. He emphasizes that integrating AI into cancer research could lead to more personalized and effective treatments, drastically improving patient outcomes and reducing costs.
Breaking studies suggest there is an alarming level of inaccuracy in clinical trial imaging data across leading cancer centers. As all cancer centers face similar challenges, these consistent findings indicate a broader crisis at hand. Join the discussion as a panel of five AACI member cancer centers discuss their own discoveries and what theyโre doing to ensure trial imaging data is accurate, compliant, and complete.
Moe Alsumidaie shares his insights in this new article addressing the accuracy crisis in clinical trial imaging. Moe explores alarming error rates of 25% to 50% and their impact on trial progression while highlighting innovative solutions like the Yunu platform, which has reduced errors to under 2%.
The clinical trial landscape faces significant challenges impacting financial outcomes and patient well-being, with clinical trial imaging errors being among the most pressing issues. These errors can lead to substantial monetary losses and skewed trial results for trial sponsors.
Over the past 30 years, there have been significant advancements in therapies and the in clinical acquisition and measurement of medical images. However, the tools and infrastructure used in clinical trial imaging workflows have largely remained unchanged.
Yunu's co-founder and CEO, Jeff Sorenson, recognizes the pivotal role marketing plays in the life sciences sector, spanning brand communication and customer awareness. Hear Jeffโs insights with Colin Miller in this SNiP, a special segment of Fractals: Life Science Conversations.
Join Fractals guest Jeff Sorenson, as he discusses transforming clinical trial imaging and accelerating results in the life sciences industry. Learn how Jeff collaborates with companies and cancer centers to revolutionize clinical trials and achieve faster time-to-market.
The Barrington James ๐ง๐ฒ๐ฐ๐ต๐ป๐ผ๐น๐ผ๐ด๐ ๐ถ๐ป ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ ๐ฝ๐ผ๐ฑ๐ฐ๐ฎ๐๐ features Yunu CEO, Jeffrey Sorenson! Listen in as Matthew Witchalls and Jeff dive into the transformative power of medical imaging and AI in clinical trials!
Our Co-Founder and Chief Science Officer, Gordon Harris, joins Blake Adams on an episode of The Next Phase podcast. Together, they explore cutting-edge solutions to intricate healthcare challenges and uncover the secrets to optimizing clinical trial efficiency.
Yunu CEO Jeffrey Sorenson recently shared insights about revolutionizing clinical trial imaging at the LSIUSA24 Emerging Medtech Summit. Discover how Yunu's cloud platform technology is transforming drug discovery.
Hear from Yunu Co-Founder & CEO, Jeff Sorenson on his experience at DPHARM 2023, how Yunu is disrupting and modernizing clinical trials, stand-out moments, and more!
Explore the many challenges of clinical trial imaging workflow and data accuracy that impact all stakeholders - from patients and research sites to CROs and sponsors.
Identify the unavoidable industry challenges in clinical trial imaging and discover Yunu's brand-new approach to guided trial workflows, timely and accurate data collection, and flawless one-touch audits.
Learn how Yunu is reducing the barriers to trial participation to ensure all eligible participants have access to advanced therapies and specialties.
